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Introduction. Isoniazid monoresistance is the most common type of single TB drug resistance 
worldwide. There is no strong evidence regarding the best treatment regimens in this group of 
patients. 
Aim of the study. To assess the impact of HR tuberculosis(TB) on treatment outcomes and 
survival among pulmonary TB patients treated under TB control program in the Republic of 
Moldova. 
Materials and methods. We have performed a comparative retrospective analysis of treatment 
outcomes in all pulmonary TB patients registered in the National Electronic TB data base (SIME 
TB) during 2012-2016. Only patients with positive culture and proven isoniazid monoresistance 
or pan-susceptibility to the first line drugs were included. 
Results. During 2012-2016, 191 monoresistant and 1889 pan-susceptible pulmonary TB cases 
were registered in SIME TB. No differences in age, gender, previous history of TB and 
comorbidities between monoresistant and pan-susceptible patients have been identified. All study 
subjects were treated with first line TB drugs regimens recommended by National Treatment 
Guidelines. Contrary to the expectations no differences were identified between pan-susceptible 
and isoniazid monoresistant subjects regarding the rates of cure(84.2% vs 84.8%, p> 0.05), 
treatment failure (3.54 vs 5.24%, p> 0.05) and death (6.65% vs 5.76%, p> 0.05). At the same 
time monoresistant subjects had a shorter treatment duration than those with pan-susceptibility 
(141 vs 224 days, p < 0.0001)  
Conclusion. Our findings suggest that compared with pan-susceptible TB, patients in with 
isoniazid monoresistant TB treated under programmatic condition in Republic of Moldova have 
similar final TB treatment outcomes including all-cause mortality. 
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Introduction. Tuberculosis is a leading cause of morbidity and mortality worldwide. According 
to the World Health Organization, 10.4 million people developed tuberculosis in 2016 and 1.7 
million people died from this disease.  
Materials and methods. We evaluated risk factors from in-hospital death in patients admitted 
with tuberculosis between January 2012 and March 2017 at a tuberculosis referral hospital in 
Borstel, Germany.  
Aim of the study. Risk factors assessment in patients with tuberculosis as mortality predictors. 
Results. Among 354 patients admitted to the Medical Clinic of the Research Center Borstel, 
Germany, 12 patients died in hospital. Median duration from admission to in-hospital death was 
70 days (Interquartile range (IQR) 23 - 129). Four variables 1) >50 pack years of cigarette 
smoking, 2) renal insufficiency, 3) diabetes mellitus and 4) >45 years of age were predictors of 
mortality in patients with tuberculosis. When none of these variables were present the risk of in-
hospital mortality was 1.0%. With 2, 3 and 4 of the variables present the risk of in-house 
mortality increased to 3.7%, 6.5%, 33% and 50%.  
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Conclusions. A simple score (CRD-45 TB-score) based on 4 clinical variables was highly 
predictive for the in-house mortality in patients with tuberculosis from this cohort. Generability 
of this score to predict in-house morbidity of patients with tuberculosis should be prospectively 
evaluated in a larger multicenter cohort. 
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Introduction. For the treatment of MDR and XDR tuberculosis, it is important to select the most 
suitable drug regimen. The resistance testing procedure should be as fast and accurate as 
possible. Within the framework of personalized medicine, the most suitable therapy approach for 
the individual patient should be found. With the faster available information from a new form of 
susceptibility testing, the best regimen could be created in a shorter period of time and the 
appropriate therapy for the patient could be initiated. 
Aim of the study. With our study we want to compare the genotypic drug resistance testing with 
phenotypic drug resistance testing. It will demonstrate to what extent the measured resistance 
results overlap and where there may be differences. 
Materials and methods. We compared the utility of genotypic DST assays with phenotypic DST 
(pDST) using Bactec 960 MGIT or Löwenstein-Jensen to construct M/XDR-TB treatment 
regimens for a cohort of 25 consecutive M/XDR-TB patients and 15 possible anti-TB drugs. 
Genotypic DST results from Cepheid GeneXpert MTB/RIF (Xpert) and line probe assays (LPAs; 
Hain GenoType MTBDRplus 2.0 and MTBDRsl 2.0) and whole-genome sequencing (WGS) 
were translated into individual algorithm-derived treatment regimens for each patient. We further 
analyzed if discrepancies between the various methods were due to flaws in the genotypic or 
phenotypic test using MIC results. 
Results. Compared with pDST, the average agreement in the number of drugs prescribed in 
genotypic regimens ranged from just 49% (95% confidence interval [CI], 39 to 59%) for Xpert 
and 63% (95% CI, 56 to 70%) for LPAs to 93% (95% CI, 88 to 98%) for WGS. Only the WGS 
regimens did not contain any drugs to which pDST showed resistance. Importantly, MIC testing 
revealed that pDST likely underestimated the true rate of resistance for key drugs (rifampin, 
levofloxacin, moxifloxacin, and kanamycin) because critical concentrations (CCs) were too high. 
Conclusions. With the analysis of the genome, even in M/XDR strains with complex resistance 
patterns it is possible to characterize these resistances. The procedure is fast and the results are 
very similar to those of phenotypic testing. Only for some drugs, the susceptibility test has to be 
carried out phenotypically in order to compile the final regimes. 
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